Deciphering the timing and impact of life-extending interventions: temporal efficacy profiler distinguishes early, midlife, and senescence phase efficacies
A growing number of compounds are reported to extend lifespan, but it remains unclear whether they reduce mortality across the entire life course or only at specific ages. This uncertainty persists because the commonly used log-rank test cannot detect age-specific effects. Here, we introduce a new analytical method that addresses this limitation by revealing when, how long, and to what extent interventions alter mortality risk. Applied to survival data from 42 compounds tested in mice by the National Institute on Aging Interventions Testing Program, it identified 22 that reduced mortality at certain ages, more than detected by the log-rank test, while 15 increased mortality at certain ages. Most compounds were effective only within restricted age ranges; just 8 reduced mortality late in life, when burdens of aging are greatest. Compared to conventional methods, this approach uncovers more beneficial and harmful effects, offers deeper insight into timing and mechanism, and can guide development of future anti-aging therapies.
In males, five compounds tested in 11 trials demonstrated reduced mortality after attainment of median lifespan, although these effects vanished before mice attained the 90% mortality benchmark: 17α-estradiol, aspirin at 21 ppm, Protandim, high doses of NDGA, and 3 of 4 late-onset (20 mo) rapamycin treatments. Notably, only 5 of the 17 compounds that reduced mortality in males did so at ages beyond the 90% mortality threshold: canagliflozin, acarbose, 17α-estradiol, glycine, rapamycin, and cocktails of either acarbose or metformin with rapamycin. In females, in contrast to males, 10 of 11 beneficial interventions reduced mortality mainly at ages after attainment of median lifespan. Five compounds reduced mortality after 90% mortality, including most trials involving rapamycin, acarbose, BD, L-leucine, and captopril.
The 8 Late-Life Mortality-Reducing Compounds
The analysis isolated a rare subset of compounds capable of reducing mortality hazard after the 90% mortality threshold of the control group.
-
Canagliflozin (Males only)
-
Acarbose (Males and Females)
-
17a-estradiol (Males only)
-
Glycine (Males only)
-
Rapamycin (Males and Females)
-
(R/S)-1,3-butanediol (BD) (Females only)
-
L-leucine (Females only)
-
Captopril (Females only)
https://www.nature.com/articles/s41467-025-65158-4
2 Likes
The Temporal Efficacy Profiler: Reassessing When Anti-Aging Compounds Actually Work
A prevailing assumption in geroscience is that life-extending compounds exert a uniform benefit across an organism’s entire lifespan. This assumption relies heavily on the log-rank test, a statistical tool that requires proportional hazards (a constant treatment effect over time). A new computational methodology, the Temporal Efficacy Profiler (TEP), challenges this paradigm by demonstrating that most longevity interventions are highly stage-specific—often reducing mortality only during early or mid-adulthood and occasionally increasing mortality at other stages.
Applying the TEP to survival data from 42 compounds tested in over 27,000 genetically heterogeneous mice by the National Institute on Aging Interventions Testing Program (ITP), researchers identified severe temporal limitations in previously celebrated compounds. The analysis uncovered 22 interventions that reduced mortality at specific ages—11 of which were completely overlooked by standard log-rank testing. More critically, the method identified 15 trials where putative longevity therapeutics actively increased mortality during certain age windows.
The data indicates that broad “geroprotection” is exceedingly rare. Most compounds lose efficacy as the subject ages, potentially due to shifting pharmacokinetics or the emergence of senescence-driven pathologies that the drugs cannot target. Out of all interventions screened, only eight specific compounds successfully reduced mortality hazard late in life, the phase when the biological burden of aging is most acute. This shift from measuring general lifespan extension to mapping age-specific mortality hazard fundamentally changes how longevity therapeutics should be screened, optimized, and dosed.
Mechanistic Deep Dive
The eight compounds capable of reducing late-stage mortality converge heavily on metabolic flexibility and nutrient-sensing pathways. Rapamycin acts directly as an mTORC1 inhibitor, driving autophagy and reducing cellular senescence. Acarbose and Canagliflozin blunt glucose spikes, indirectly modulating the AMPK/mTOR axis to simulate caloric restriction. (R/S)-1,3-butanediol forces a transition to ketone body metabolism, while L-leucine and Glycine modulate amino acid sensing and potentially buffer methionine restriction pathways. Captopril acts on the renin-angiotensin system, suggesting that late-stage female mortality is heavily gated by vascular and renal degradation. The failure of antioxidant and generalized anti-inflammatory compounds to reach late-stage efficacy suggests that basic metabolic reprogramming is the primary requisite for pushing maximum lifespan limits. [Confidence: Medium]
Institution: UT Health San Antonio & South Texas Veterans Health Care System Country: USA Journal: Nature Communications
Impact Evaluation: The impact score of this journal is 15.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.
1 Like